Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform
December 14, 2022 08:00 ET | Source: Third Pole Therapeutics Funding will support the final development phase prior to planned 2023 FDA submission of the company’s “breakthrough” designated eNOcare™ hospital device WALTHAM, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) — Third Pole … Continued